NEXTracker Option Alert: Jan, 2026 $50 Puts at the Ask: 649 vs 1028 OI

NEXTracker Option Alert: Jan, 2026 $50 Puts at the Ask: 649 @ $10.5 vs 1028 OI; Ref=$47.3

NEXTracker Option Alert: Jan, 2026 $50 Puts Sweep (16) near the Ask: 1000 vs 1028 OI

NEXTracker Option Alert: Jan, 2026 $50 Puts Sweep (16) near the Ask: 1000 @ $10.5 vs 1028 OI; Ref=$47.22

NEXTracker (NASDAQ:NXT) 株価情報

NEXTRACKER INC-CL A

NEXTracker

Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.

NEXTracker Inc

NEXT BIOMETRICS GRP ORD by Next Biometrics Group AS

Next Biometrics Group ASA

NextCure Inc

NEXTGEN DIGITAL PLATFORMS by NextGen Digital Platforms Inc.

Nextgen Digital Platforms Inc

Investment Managers Series Trust II AXS Green Alpha ETF

NEXTRACTION ENERGY CORP by Nextraction Energy Corp.

Nextraction Energy Corp

First Trust Indxx NextG ETF

NXT NUTRITIONALS HLDG INC by NXT Nutritionals Holdings, Inc.

NXT Nutritionals Holdings Inc

Simplify Exchange Traded Funds Simplify Next Intangible Core Index ETF

Next10 Inc

NEXSTIM OYJ by NEXSTIM OYJ

NEXTPLAY TECHS INC by NextPlay Technologies, Inc.

NextPlay Technologies Inc

Next Technology Holding Inc. - Ordinary Shares

Next Technology Holding Inc

Lifeist Wellness Inc

Simplify Exchange Traded Funds Simplify Next Intangible Value Index ETF

NEXITY FINANCIAL CORP by Nexity Financial Corp.

Nexity Financial Corp

XAGEW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Keybanc analyst Sophie Karp downgrades Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) from Sector Weight to Underweight and announces $78 price target.

News

Downgrades

Price Target

Analyst Ratings

Keybanc Downgrades Southern to Underweight, Announces $78 Price Target

WIIM

ABSI

Absci shares are trading higher after the company announced it began dosing the first participants in its Phase 1 ABS-101 clinical trial.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Mike Matson upgraded the rating for Establishment Labs Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) from Hold to Buy and announced a $48 price target. Establishment Labs shares closed at $34.96 on Tuesday. <a href="https://www.benzinga.com/quote/esta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Ashley Helgans upgraded PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Hold to Buy and raised the price target from $70 to $105. PVH shares closed at $80.50 on Tuesday. <a href="https://www.benzinga.com/quote/pvh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Geoff Meacham upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Neutral to Buy and raised the price target from $600 to $700. Regeneron Pharmaceuticals shares closed at $574.16 on Tuesday. <a href="https://www.benzinga.com/quote/regn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stan Berenshteyn upgraded the rating for Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Equal-Weight to Overweight and raised the price target from $31 to $35. Omnicell shares closed at $28.00 on Tuesday. <a href="https://www.benzinga.com/quote/omcl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Sophie Karp upgraded the rating for Ameren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) from Sector Weight to Overweight and announced a $103 price target. Ameren shares closed at $94.32 on Tuesday. <a href="https://www.benzinga.com/quote/aee/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PVH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-1024x586.png" alt="" class="wp-image-914981" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

ESTA

OMCL

REGN

This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Keybanc analyst Sophie Karp downgrades Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) from Overweight to Sector Weight and maintains the price target from $51 to $51.

Keybanc Downgrades Portland Gen Electric to Sector Weight, Maintains Price Target to $51

NOTICE OF ACTION TAKEN BY WRITTEN CONSENT OF THE HOLDERS OF A
MAJORITY OF THE VOTING POWER OF OUR CAPITAL STOCK
&nbsp;
To Our Stockholders:
&nbsp;
This information statement (the "Information Statement") is first being furnished by Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the "Company", "we", "us", "our", or "Cyclacel") on or about May 23, 2025 to the holders of record of the outstanding common stock of the Company, $0.001 par value per share (the "Common Stock"), pursuant to Rule 14c-2 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This Information Statement relates to actions taken by written consent in lieu of a meeting, on May 12, 2025 (the "Written Consent") by the stockholder owning a majority of shares of Common Stock issued and outstanding (the "Majority Consenting Stockholder") of the Company.
&nbsp;
The Written Consent constitutes the consent of the Majority Consenting Stockholder and is sufficient under the General Corporation Law of the State of Delaware and our bylaws, as amended (the "Bylaws") to approve the actions described herein. Accordingly, they are not presently being submitted to our other stockholders for a vote. Pursuant to Rule 14c-2 under the Exchange Act, the actions described herein will not be implemented until a date at least 20 days after the date on which this Information Statement has been first mailed to the stockholders.
&nbsp;
The Written Consent authorized the Company's board of directors (the "Board") to amend the Company's amended and restated certificate of incorporation, as amended (the "Certificate of Incorporation") to effect a reverse stock split of all outstanding shares of Common Stock, by a ratio that will not be less than one-for-three (1:3) or exceed a ratio of one-for-hundred (1:100) (the "Approved Split Ratios"), to be determined in the Board's sole discretion.
&nbsp;
As described in this Information Statement, the foregoing actions were approved by the Majority Consenting Stockholder by Written Consent and subsequently approved unanimously by the Board.
&nbsp;
The cost of furnishing this Information Statement will be borne by the Company. The Company may request brokerage houses, nominees, custodians, fiduciaries and other like parties to forward this Information Statement to the beneficial owners of Common Stock held of record by them and will reimburse such persons for their reasonable charges and expenses in connection therewith. This Information Statement will be first distributed to you on or about May 23, 2025.
&nbsp;

Stock Split

CYCC

Cyclacel Pharmaceuticals Announces Majority Stockholder And Board Approval Of Reverse Stock Split At A Ratio Between 1-For-3 And 1-For-100

TXO Partners shares are trading lower after the company announced a $175 million public offering.

The Port of Los Angeles, one of the largest import gateways in the U.S., has issued a warning that the recent reduction in tariffs on Chinese goods may not be enough to reverse the declining cargo volume.
What Happened: Cargo volumes at the Port of Los Angeles have been on a downward trend. To avoid new tariffs, companies previously stockpiled inventory but have since halted or canceled new orders, prompting shipping firms to cancel numerous upcoming sailings, as per <a href="https://www.wsj.com/articles/china-tariff-rollback-unlikely-to-boost-imports-port-of-l-a-chief-says-c9d8078f?mod=business_feat7_logistics_pos2">report</a> from the Wall Street Journal. 
The port&#8217;s executive director, Gene Seroka, predicts a 25% year-over-year drop in imports for May. He remains doubtful that the recent tariff reduction from 145% to 30% on Chinese imports will lead to a significant increase in cargo volume. &#8220;Even at a 30% tariff with a 90-day reprieve, it&#8217;s not going to dramatically change what we&#8217;re seeing right now,&#8221; Seroka told the Wall Street Journal.
Although some retailers may see short-term benefits from reduced tariffs while preparing for peak seasons such as holiday and back-to-school, Seroka does not expect cargo volumes to return to previous levels in recent weeks and months. &#8220;Reason being, you're not going to be frontloading at 30%.", he said.
Why It Matters: This warning comes on the heels of a <a href="https://www.benzinga.com/25/05/45254241/recession-could-originate-at-the-port-of-los-angeles-warns-economist-calling-tariff-decision-a-misapplied-consumption-tax-on-households">prediction</a> by RSM chief economist Joseph Brusuelas of a potential tariff-induced recession originating from the Los Angeles docks. He described the tariff decision as a "misapplied consumption tax" that could halt economic expansion prematurely.
Furthermore, a&nbsp;<a href="https://www.benzinga.com/markets/25/05/45335936/no-cargo-vessels-en-route-from-china-to-california-for-first-time-since-pandemic">recent report</a>&nbsp;highlighted that for the first time since the COVID pandemic, no cargo ships were en route from China to the two primary ports in California. This sudden halt in trade followed the Trump administration&#8217;s imposition of substantial tariffs on Chinese imports.
Meanwhile, shipping rates have remained stable, with spot rates from Asia to the U.S. West Coast at $2,321 as of May 7, as per Freightos Baltic Index. Freightos&#8217; Judah Levine expects rates to rise moderately, not sharply, as a volume rebound may trigger an early peak season.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/25/05/45399783/gordon-johnson-warns-of-potential-liberation-day-20-as-30-year-treasury-yields-approach-5-amid-dollar-weakness" target="_blank" rel="noreferrer noopener">Gordon Johnson Warns Of Potential &#8216;Liberation Day 2.0&#8217; As 30-Year Treasury Yields Approach 5% Amid Dollar Weakness</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

US-China Tariff Truce May Not Revive Imports, Says Port Of LA Chief: 'You're Not Going To Be Frontloading At 30%'

Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology
NORTH CHICAGO, Ill. and SAN DIEGO, May 14, 2025 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.
siRNA represents a class of molecules capable of regulating gene expression and protein production. Unlike traditional modalities such as antibodies and small molecules, siRNA regulates the expression of genes. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins.
The strategic collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential to enable sustained and precise mRNA silencing. AbbVie will contribute its expertise in antibody engineering, antibody drug conjugates (ADCs) and tissue delivery approaches as appropriate, to augment ADARx's discovery efforts.

ABBV

AbbVie And ADARx Pharma Announce Collaboration And License Option Agreement To Develop siRNA Therapeutics Across Multiple Disease Areas, Including Neuroscience, Immunology And Oncology

Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/25/05/45401873/us-stock-futures-waver-after-a-mixed-close-sp-500-is-flashing-quite-rare-and-rather-bullish-signal-says-expert" rel="noreferrer noopener">premarket session on Wednesday</a>.
On Tuesday, the company reported earnings per share of 72 cents loss, <a href="https://www.benzinga.com/pressreleases/25/05/n45394089/innovative-eyewear-inc-reports-q1-2025-unaudited-financial-results" target="_blank" rel="noreferrer noopener">beating the Street estimate of 73 cents loss</a>. Quarterly sales of  $454.50 thousand (up 19% year over year) missed the analyst consensus estimate of one million dollars.
This increase was primarily attributable to growth in unit sales volume, driven by product launches during 2024 of the co-branded Nautica&nbsp;Powered by Lucyd&nbsp;and Eddie Bauer&nbsp;Powered by Lucyd&nbsp;collections and the Lucyd Armor safety smart glasses line.
The gross profit margin for the quarter was 49%, compared with 2% in the year-ago period, driven by lower cost of frames and lower prescription lens fulfillment cost.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45402352/american-eagle-cisco-systems-and-3-stocks-to-watch-heading-into-wednesday" rel="noreferrer noopener">American Eagle, Cisco Systems And 3 Stocks To Watch Heading Into Wednesday</a>
&#8220;As we look ahead to the rest of 2025, we believe we are well positioned to build on our momentum and significantly grow total revenues and market share,&#8221; said Harrison Gross, CEO of Innovative Eyewear.
Gross highlighted the company&#8217;s potential in the newly launched Reebok product line, which expanded its portfolio to include smart glasses for active lifestyles and the continued significant traction of the Lucyd ArmorTM&nbsp;smart safety glasses.
&#8220;Both product lines address vast subsets of the eyewear market which were previously underserved by smart eyewear providers,&#8221; the CEO added.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, LUCY stock has lost over 50% in the past year.
Price Action: LUCY shares are trading higher by 53% to $3.030 premarket at last check on Wednesday.
Check This Out:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock" target="_blank" rel="noreferrer noopener">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a></li>
</ul>
Image by Sutthiphong Chandaeng via Shutterstock

Earnings

Equities

Movers

General

LUCY

What's Going On With Innovative Eyewear Stock On Wednesday?

NUTX

Nutex Health shares are trading higher after the company reported better-than-expected Q1 financial results.

Offerings

GNPX

Genprex Files For Offering Of 27,586,206 Shares Together With Warrants At $0.29 Per Share And Warrant

MP Materials shares are trading higher after the company reached an agreement with a Saudi Arabian mining company to explore and establish a fully integrated end-to-end rare earth supply chain.

MYNZ

Mainz Biomed Files For Offer Of 2.,448,980 Ordinary Units And 2,488,988 Pre-Funded Units

Keybanc analyst Ashley Owens maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Overweight and raises the price target from $60 to $68.

ONON

Keybanc Maintains Overweight on On Holding, Raises Price Target to $68

MLEC

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

<a href="https://www.bloomberg.com/news/articles/2025-05-14/roche-warns-us-investments-at-risk-from-trump-drug-price-plans" title="https://www.bloomberg.com/news/articles/2025-05-14/roche-warns-us-investments-at-risk-from-trump-drug-price-plans">https://www.bloomberg.com/news/articles/2025-05-14/roche-warns-us-investments-at-risk-from-trump-drug-price-plans</a>

Biotech

RHHBY

'Roche Warns US Investments at Risk From Trump Drug Price Plans' - Bloomberg News

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073427/Bear-Repellant-1024x683.jpeg" alt="" class="wp-image-12914" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073427/Bear-Repellant-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073427/Bear-Repellant-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073427/Bear-Repellant-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073427/Bear-Repellant.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Be Fearful When Others Have FOMO</h2>
It&#8217;s natural to have some FOMO (Fear of missing out) after the rally we&#8217;ve had off the April lows. I have some myself. At the end of March, I&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-adjustments">guessed correctly</a>&nbsp;that shares of&nbsp;Robinhood Markets&nbsp;(HOOD), a Portfolio Armor&nbsp;<a href="https://portfolioarmor.com/performance-top-names">top ten name</a>&nbsp;at the time, were probably near a bottom. As I wrote then, in a pre-market note, when the futures were a sea of red:&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">I'm lowering the strike on these HOOD puts by $2. This puts our break even on the stock at $34, which is about its 200-day exponential moving average, which seems like a plausible near-term bottom for it.
</blockquote>
But instead of buying OTM (out of the money) calls on HOOD, I sold puts on it.&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">The stock is Robinhood Markets (HOOD 0.05%↑), which I think would be a great long term holding if we can get it in the $30s. So I placed a GTC order to sell the $38 strike put on it expiring on May 9th for $4. If that put gets exercised, I will have effectively bought the stock for $34. The max gain on one contract is $400, the max loss is $3,400 (assuming the put gets exercised, and then the stock goes to zero), and the break even is with HOOD at $34. <s>This trade hasn't filled yet</s>. This trade filled at $4.30 on 4/3/2025.
</blockquote>
<h2 class="wp-block-heading">Avoiding FOMO And ROMO</h2>
I see shares of Robinhood trading in the low $60s now and realize I could have made ~2,000% buying OTM calls back then instead. Same with&nbsp;Palantir Technologies&nbsp;(PLTR), another PA top name at the time. I made some modest profits (~150% gains) on some relatively conservative options trades on it, but OTM calls on that would would be up &gt;10x now too.
Maybe FOMO&#8217;s the wrong word for what I have. It&#8217;s more like ROMO (Regret of missing out). But some of you reading this probably do have FOMO, and are tempted to buy now.&nbsp;
<h2 class="wp-block-heading">So What To Do Now?&nbsp;</h2>
Be ready if there&#8217;s another leg down. Then you might get a chance to buy your favorite stock for less. Here&#8217;s why that might happen this summer.&nbsp;
Despite the bullish headlines this week—trade agreements, easing tensions between the U.S. and China, and market technicals pointing toward continued upward momentum—there&#8217;s still cause for concern.
First, Treasury bond yields remain elevated, signaling persistent concerns over inflation and higher-for-longer interest rates. Even with some positive trade news, bond investors seem skeptical that inflation has been beaten, or that the Fed will be quick to cut rates.&nbsp;
Secondly, the current U.S.-China trade deal includes only a temporary, 90-day suspension of new tariffs. The risk remains high that tensions could reignite, particularly if either side perceives a lack of follow-through on promised concessions. Markets have repeatedly underestimated the fragility of trade truces in the past, leading to sudden and sharp reversals.
Plus, economic damage from months of elevated tariffs and disrupted trade flows may already be baked in. Manufacturers, retailers, and global supply chains have absorbed significant costs and disruptions, which can continue to weigh on earnings and consumer spending even after an initial deal is struck.
Finally, valuations in major indices remain stretched relative to historical averages, leaving little room for error.
<h2 class="wp-block-heading">The Case For Bear Repellant&nbsp;</h2>
If you&#8217;re fully invested now, and we get another leg down in the market this summer, you won&#8217;t have any dry powder to buy beaten-down stocks with. If you take the opposite tack, and just stay in cash, you&#8217;ll have two other problems. First, FOMO may become irresistible. Second, if the market keeps going higher for the rest of the year&#8211;or longer&#8211;you&#8217;re going to miss out on all those gains.&nbsp;
A little bear repellant (hedging) goes a long way. One or two percent of your portfolio in option hedges can balloon to a sizeable position in a market crash. Your appreciated options will be dry powder you can convert to cash to buy stocks near the bottom. If you want an easy way to find optimal hedges, you can download the Portfolio Armor app by&nbsp;aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073615/PA-JPEG-4-1024x683.jpeg" alt="" class="wp-image-12915" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073615/PA-JPEG-4-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073615/PA-JPEG-4-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073615/PA-JPEG-4-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073615/PA-JPEG-4.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
And if you want to avoid ROMO with me next time, you can subscribe to the Portfolio Armor trading Substack/occasional email list below. Next time the market tanks, I&#8217;ll be swinging for the fences.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to <a href="https://portfolioarmor.substack.com/">our trading Substack</a> using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073847/Widget-4.jpg" alt="" class="wp-image-12916" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073847/Widget-4.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14073847/Widget-4-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Options

Opinion

Be Fearful When Others Have FOMO

Keybanc analyst Sophie Karp downgrades Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) from Sector Weight to Underweight and announces $39 price target.

Keybanc Downgrades Exelon to Underweight, Announces $39 Price Target

As of May 14, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Diversified Healthcare Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHC#NASDAQ">DHC</a>)</h3>
<ul class="wp-block-list">
<li>On May 5, Diversified Healthcare reported first-quarter financial results and beat its FFO and sales estimates. The company's stock jumped around 47% over the past month and has a 52-week high of $4.24.</li>
<li>RSI Value: 75.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>DHC Price Action: Shares of Diversified Healthcare Trust gained 2% to close at $3.05 on Tuesday.</li>
<li>Edge Stock Ratings: 84.97 Momentum score with Value at 84.66. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/dhc"><img loading="lazy" decoding="async" width="491" height="166" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14043136/image-155.png" alt="" class="wp-image-914609" style="width:370px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14043136/image-155.png 491w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14043136/image-155-300x101.png 300w" sizes="(max-width: 491px) 100vw, 491px" /></a></figure>
<h3 class="wp-block-heading">Douglas Elliman Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>)</h3>
<ul class="wp-block-list">
<li>On May 1, Douglas Elliman reported better-than-expected first-quarter sales results. &#8220;Our performance in the first quarter highlights the strength of our luxury brand and the incredible efforts of our agents, employees and leadership team,&#8221; said Michael S. Liebowitz, Chief Executive Officer of Douglas Elliman Inc. &#8220;By focusing on high-impact areas like Development Marketing, we&#8217;re driving growth and reinforcing our position as the leader in the luxury market – delivering our highest first-quarter revenue since 2022 with significant reductions in operating losses.&#8221; The company's stock gained around 23% over the past month and <a href="https://www.benzinga.com/quote/DOUG">has a 52-week high</a> of $2.98.</li>
<li>RSI Value: 76.8</li>
<li>DOUG Price Action: Shares of Douglas Elliman gained 7.9% to close at $2.04 on Tuesday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a></li>
</ul>
Photo via Shutterstock

Short Ideas

DOUG

Top 2 Real Estate Stocks That May Collapse In Q2

Press Releases

NXT Investors Have Opportunity to Lead Nextracker Inc. Securities Fraud Lawsuit with the Schall Law Firm

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nextracker

Legal

Nextracker Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 25, 2025 Deadline to file Lead Plaintiff Motion

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Nextracker, Inc. (NASDAQ: NXT); Driven Brands Holdings, Inc. (NASDAQ: DRVN); Extreme Networks, Inc. (NASDAQ: EXTR); and MGP Ingredients, Inc. (NASDAQ: MGPI)

FINAL SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nextracker

NEXTRACKER ALERT: Bragar Eagel & Squire, P.C. is Investigating Nextracker Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Attention Long-Term Shareholders of Dominos Pizza Corp. (NASDAQ: DPZ); Driven Brands Holdings, Inc. (NASDAQ: DRVN); Extreme Networks, Inc. (NASDAQ: EXTR); and Nextracker, Inc. (NASDAQ: NXT): Grabar Law is Investigating Claims on Your Behalf

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
10:58 AMFeb 14, 2025	PUT	$50.00	Jan 16, 2026	246	1700	649	165	1028	TRADE	BEARISH
10:55 AMFeb 14, 2025	PUT	$50.00	Jan 16, 2026	246	1001	1000	97	1028	SWEEP	BEARISH

Comments

NEXTracker

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル